3D Medicines (HKG: 1244) announced the enrollment of the first patient in a Phase III clinical trial evaluating envafolimab as a neoadjuvant/adjuvant therapy for resectable Stage III non-small cell lung cancer (NSCLC).
Contents
Clinical Trial Overview
| Item | Detail |
|---|---|
| Trial Phase | Phase III |
| Design | Randomized, double-blind, placebo-controlled, multicenter |
| Patient Population | Approximately 390 patients with resectable Stage III NSCLC |
| Clinical Sites | ~60 sites across China |
| Primary Endpoints | Event-free survival (EFS), major pathological response (MPR) rate, pathological complete response (pCR) rate |
| Treatment Arms | Envafolimab + platinum-doublet chemotherapy vs. placebo + platinum-doublet chemotherapy |
Drug Profile & Development History
- Molecule: Envafolimab – the world’s first commercially available subcutaneously injected PD-L1 inhibitor
- Initial Approval: Conditionally approved in China for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors
- Development Timeline: Initially developed by Alphamab Oncology, joint development with 3D Medicines since 2016
- Strategic Alliance: On March 30, 2020, a three-way collaboration formed among Alphamab Oncology, 3D Medicines, and Simcere Pharmaceutical Group, with responsibilities divided for production, development, and commercialization respectively
Market Context & Strategic Significance
- NSCLC Landscape: Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases globally, with Stage III representing a critical treatment window where neoadjuvant/adjuvant therapy can significantly impact long-term outcomes
- Therapeutic Innovation: Subcutaneous administration offers significant patient convenience advantages over intravenous PD-(L)1 inhibitors, potentially improving compliance and reducing healthcare resource utilization
- Commercial Potential: If successful, this trial could expand envafolimab’s label to include early-stage NSCLC, creating a substantial new revenue stream beyond its current oncology indications
- Competitive Positioning: The subcutaneous formulation differentiates envafolimab from competing PD-L1 inhibitors like AstraZeneca’s Imfinzi and Roche’s Tecentriq, which require IV infusion
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial timelines, regulatory approvals, and commercial expectations for envafolimab. Actual results may differ due to risks including trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech
